论文部分内容阅读
目的:观察和分析对乙肝肝硬化患者采用恩替卡韦和复方鳖甲软肝片联合进行治疗的临床疗效。方法:选取2013年3月至2015年3月间我院收治的乙肝肝硬化患者100例作为临床研究对象,使用随机数字列表法将其随机分成研究组(n=50例)和对照组(n=50例)。对照组患者单纯采用恩替卡韦进行治疗,研究组患者在对照组的治疗基础上加用复方鳖甲软肝片联合进行治疗。观察和比较两组患者的治疗效果。结果:研究组患者治疗后的总有效率为(96.0%),明显高于对照组(78.0%),P<0.05,差异均有统计学意义。结论:对乙肝肝硬化患者采用恩替卡韦和复方鳖甲软肝片联合进行治疗具有良好的临床疗效,值得在临床上进一步推广。
Objective: To observe and analyze the clinical efficacy of entecavir and Fufang Biejia Ruangan Pian in patients with hepatitis B cirrhosis. Methods: A total of 100 patients with hepatitis B cirrhosis admitted to our hospital from March 2013 to March 2015 were selected as the clinical study subjects. They were randomly divided into study group (n = 50) and control group (n = 50) using random number list method = 50 cases). Patients in the control group were treated with entecavir alone. Patients in the study group were treated with Fufang Biejia Ruangan Pian on the basis of the control group. Observed and compared the treatment effect of two groups of patients. Results: The total effective rate of the study group after treatment was (96.0%), significantly higher than that of the control group (78.0%), P <0.05, the difference was statistically significant. Conclusion: The treatment of hepatitis B cirrhosis patients with entecavir and Fufang Biejia Ruangan Pian has a good clinical curative effect, which is worth further promotion in clinic.